Large real-world study found apixaban, edoxaban, and rivaroxaban offer similar dementia protection in atrial fibrillation, allowing clinicians to prioritize safety, adherence, and patient-specific factors.
Comments
0
Be the first to comment
Sign up now and become a member of the TheBrief.Health community!
Comments
0Be the first to comment
Sign up now and become a member of the TheBrief.Health community!